Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Barrier restoring capacity of Dupilumab in CRSwNP
2023-504014-30-00Phase 4Completed
- Sponsor
- UZ Leuven
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma comparing Dupixent add-on with Placebo add-on (2 arms). Started Nov 2023; status: completed.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)asthma
Beyond the preview
Go deeper on 2023-504014-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504014-30-00.